Fig. 4: Neutralisation of CXCL12 chemokine gradient abrogates the mobilisation of MSCs in response to β3AR activation. | npj Regenerative Medicine

Fig. 4: Neutralisation of CXCL12 chemokine gradient abrogates the mobilisation of MSCs in response to β3AR activation.

From: Pharmacological tools to mobilise mesenchymal stromal cells into the blood promote bone formation after surgery

Fig. 4: Neutralisation of CXCL12 chemokine gradient abrogates the mobilisation of MSCs in response to β3AR activation.The alternative text for this image may have been generated using AI.

a, b Mice were pretreated with BRL37344 (β3) or vehicle once daily on 4 consecutive days. One hour after the last injection, mice were administered AMD3100 and 1 h later femoral bone marrow and blood was collected for quantification of CXCL12 in a bone marrow (BM) supernatant and b peripheral blood (PB) plasma, respectively; n = 6–13 mice per group. CXCL12 levels are shown as pg per ml. c, d Experimental design; mice were pretreated (PT) with BRL37344 (β3) or vehicle once daily for 4 days. 1 h after the last injection, mice were administered AMD3100 in the presence or absence of chalcone 4-phosphate (C4P), a CXCL12 neutraligand (NL), and 1 h later blood was collected for analysis of d circulating CFU-Fs; n = 6–8 mice per group. CFU-Fs are shown as colonies per ml of blood. (a–d) Data of at least two independent experiments represented as mean ± s.e.m.; **P < 0.01,***P < 0.001 (one-way ANOVA with Bonferroni correction).

Back to article page